Amgen Inc

Затворен

СекторЗдравеопазване

358.19 0.34

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

353

Максимум

360.6

Ключови измерители

By Trading Economics

Приходи

486M

1.8B

Продажби

-1.3B

8.6B

P/E

Средно за сектора

25.5

60.549

EPS

5.15

Дивидентна доходност

2.58

Марж на печалбата

21.107

Служители

31,500

EBITDA

-1.2B

3.9B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-0.36% downside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

2.58%

2.22%

Следващи печалби

4.08.2026 г.

Следваща дата на дивидент

11.09.2026 г.

Следваща дата на екс-дивидент

21.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

14B

198B

Предишно отваряне

357.85

Предишно затваряне

358.19

Настроения в новините

By Acuity

5%

95%

2 / 342 Класиране в Healthcare

Amgen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.07.2026 г., 19:46 ч. UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

10.07.2026 г., 23:16 ч. UTC

Amgen Inc. shares are higher in after-market trading, remaining near the upper end of their one-month range amid rising U.S. Treasury yields.

9.07.2026 г., 23:01 ч. UTC

Amgen Inc shares are trading lower in after-market hours, following unusual trading activity with no specific news identified to explain the decline.

8.07.2026 г., 23:21 ч. UTC

Amgen Inc shares are lower in after-market hours, reflecting broader market declines amid geopolitical tensions and a significant drop in the DAX 30 Index.

7.07.2026 г., 19:06 ч. UTC

News

Truist Securities raised Amgen's price target to $340, maintaining a Hold rating. Shares are advancing, reflecting positive sentiment and long-term value creation.

6.07.2026 г., 20:06 ч. UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2.07.2026 г., 23:06 ч. UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

1.07.2026 г., 19:11 ч. UTC

Social Media

Amgen Inc shares are lower amid social media discussions on AI's impact on drug discovery and client platform risk perceptions in the biopharma sector.

29.06.2026 г., 19:11 ч. UTC

News

Amgen Inc shares are higher today, supported by a broader market rally and investor confidence from South Korea's $576 billion investment plan in technology.

26.06.2026 г., 23:06 ч. UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

25.06.2026 г., 23:01 ч. UTC

Amgen Inc shares are higher in after-market trading, continuing a recent positive trend with four consecutive sessions of gains. No specific news was identified.

24.06.2026 г., 23:01 ч. UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23.06.2026 г., 20:06 ч. UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22.06.2026 г., 19:33 ч. UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18.06.2026 г., 22:06 ч. UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17.06.2026 г., 19:53 ч. UTC

Macro Event

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16.06.2026 г., 19:22 ч. UTC

News

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15.06.2026 г., 21:09 ч. UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12.06.2026 г., 19:51 ч. UTC

News

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11.06.2026 г., 23:06 ч. UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10.06.2026 г., 23:51 ч. UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9.06.2026 г., 19:56 ч. UTC

News

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8.06.2026 г., 20:06 ч. UTC

News

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5.06.2026 г., 23:01 ч. UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4.06.2026 г., 23:51 ч. UTC

News

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3.06.2026 г., 23:41 ч. UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2.06.2026 г., 23:02 ч. UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1.06.2026 г., 20:02 ч. UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29.05.2026 г., 20:06 ч. UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28.05.2026 г., 23:56 ч. UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

Сравнение с други в отрасъла

Ценова промяна

Amgen Inc Прогноза

Ценова цел

By TipRanks

-0.36% надолу

12-месечна прогноза

Среден 359.17 USD  -0.36%

Висок 427 USD

Нисък 300 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за Amgen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

24 ratings

10

Купи

13

Задържане

1

Продай

Настроение

By Acuity

2 / 342 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat